Because of the potential interactions of angiotensin-converting-enzyme (ACE) with SARS-CoV-2, there were initially some concerns as to whether ACE inhibitors and related angiotensin receptor blockers (ARBs) would impact the course of COVID-19. This evidence concerns the gene ACE and COVID-19.